



Lab Resource: Stem Cell Line

Generation of human induced pluripotent stem cell line from a patient with a long QT syndrome type 2



Azra Fatima^a, Dina Ivanyuk^a, Stefan Herms^{b,c}, Stefanie Heilmann-Heimbach^b, Orla O'Shea^d, Charlotte Chapman^d, Zsuzsanna Izsvák^e, Martin Farr^f, Jürgen Hescheler^a, Tomo Šarić^{a,*}

^a Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty, University of Cologne, Cologne, Germany

^b Institute for Human Genetics, University of Bonn, Bonn, Germany and Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany

^c Research group Genomics, Medical Genetics, University Hospital Basel, Department of Biomedicine, Basel, Switzerland

^d UK Stem Cell Bank, Division of Advanced Therapies, National Institute for Biological Standards and Control, Hertfordshire, UK

^e Max-Delbrück-Center for Molecular Medicine in the Helmholtz Society, Berlin, Germany

^f Heart- and Diabetes Center NRW, Laboratory of the Clinic for Cardiology, University Hospital of the Ruhr-University Bochum, Bad Oeynhausen, Germany

ARTICLE INFO

Article history:

Received 31 December 2015

Accepted 31 December 2015

Available online 6 January 2016

ABSTRACT

We report here the generation of human iPSC cell line UKKi009-A from dermal fibroblasts of a patient carrying heterozygous mutation c.3035–3045delTCCCTCGATGC, p.Leu1012Pro (fs*55) in KCNH2 gene leading to long QT syndrome type 2 (LQT2). We used the Sleeping Beauty transposon-based plasmids expressing OSKM along with microRNAs 307/367 to reprogram the fibroblasts. The iPSC cells possess pluripotent stem cell characteristics and differentiate to cell lineages of all three germ layers. This cell line can serve as a source for in vitro modeling of LQT2. This cell line is distributed by the European Collection of Authenticated Cell Cultures (ECACC).

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Resource Table

Name of stem cell line	UKKi009-A
Alternative name	NP0011-8
Institution	Institute for Neurophysiology, Medical Faculty, University of Cologne, Germany
Person who created resource	Dina Ivanyuk
Contact person and email	Tomo Saric, tomo.saric@uni-koeln.de
Date archived/stock date	29th August 2014
Origin	Dermal fibroblasts
Sex	Female
Disease status	Long QT syndrome type 2 (LQT2; OMIM entry # 613688)
Mutation	Heterozygous mutation c.3035–3045delTCCCTCGATGC, p.Leu1012Pro (fs*55) in KCNH2 gene
Type of resource	iPSC cell line for disease modeling, drug and toxicity testing
Sub-type	hiPSC, derived from dermal fibroblast, no genetic modification
Key transcription factors	POU5F1, SOX2, KLF4, MYC
Authentication	Identity was confirmed by DNA sequencing (Fig. 1C) SNP genotyping (Table 1) and STR analysis of six markers (Fig. 2)

Other clonal lines available	UKKi009-B (NP0011-19) iPSC cell line; http://hpscrg.eu/cell-line/UKKi009-B
Link to related literature	None
Information in public databases	http://hpscrg.eu/cell-line/UKKi009-A
Ethics	Consent from the donor of the tissue has been obtained, Ethics Review Board/competent authority approval has been obtained

Resource details

The human iPSC line was generated by reprogramming of fibroblasts cultured from skin biopsy of a 32 year old patient suffering from LQT syndrome Type 2 (LQT2). LQT syndrome is a medical condition, either genetic or acquired, described after its characteristic electrocardiogram showing a prolonged cardiac repolarization phase resulting in a long QT interval. The clinical symptoms of LQTS include palpitations, syncope, seizures leading to sudden cardiac death. The patient carried a heterozygous mutation in KCNH2 gene c.3035_3045delTCCCTCGATGC leading to amino acid frame shift beginning at Leucine 1012 (p.Leu1012Pro, fs*55). Fibroblasts were reprogrammed by transposition of OCT4, SOX2, KLF4 and c-MYC (OSKM) and miRNA302/367 expression cassettes mobilized by the SB100X hyperactive transposase (Grabundzija et al., 2013). The reprogramming was performed on murine embryonic fibroblast (MEFs) in the presence of valproic acid and vitamin C for 7 days after transfection. After isolation and initial expansion, the iPSC cells were maintained in a feeder-free system on vitronectin-coated plates in

* Corresponding author.

E-mail address: tomo.saric@uni-koeln.de (T. Šarić).




Fig. 1. Characterization of human iPS cell line UKKi009-A. A. Morphology of iPS cell colonies as observed by bright field microscopy (left image: 10×, right image: 32×). B. Immunostaining for OCT4, NANOG, TRA-1-80 and SSEA4 showing the iPS colonies uniformly expressing the markers. C. Expression of pluripotent stem cell markers TRA-1-80 and SSEA4 on the surface of UKKi009-A iPS cells as measured by flow cytometry. D. Assessment of pluripotency of iPS cells by RT-qPCR analysis of expression of indicated germ layer-specific transcripts at day 14 of differentiation compared against undifferentiated cells as a control using the $\Delta\Delta Ct$ method. E. RT-PCR showing absence of transgenes SOX2 and c-MYC (left panel) and OCT4 and KLF4 (right panel) expression in iPS cells. Plasmid encoding OSKM cassette was used as a positive control. Arrows indicate the expected band size (1848 bp and 1364 bp for left and right panel, respectively). M = DNA-size marker. F. DNA sequence showing the presence of mutation c.3035-3045delTCCCTCGATGC in the KCNH2 gene of patient-derived dermal fibroblasts (hDFs) and UKKi009-A iPS cells derived from them. The nucleotide sequence indicated beneath the sequencing chromatogram is the NCBI Reference Sequence: XM_011516185.1. G. Single nucleotide polymorphism (SNP) genotyping reveals identity of UKKi009-A iPS cells with NPO011 patient-derived hDFs but not with hDFs derived from an unrelated donor NPO022.

Essential 8 (E8) medium. They exhibited morphology similar to those of human embryonic stem (ES) cells (Fig. 1A) and expressed endogenous self-renewal genes OCT4, NANOG and the pluripotent stem cell markers TRA-1-80 and SSEA4 at the protein level as demonstrated by immunocytochemistry (Fig. 1B) and flow cytometry (Fig. 1C). The pluripotency was further demonstrated in vitro by embryoid body (EB)-based differentiation to endodermal, mesodermal and ectodermal cell lineages (Fig. 1D). Cardiac differentiation was confirmed by identification of spontaneously beating cells (Supplemental video 1). This iPS cell line did not express transcripts of exogenous reprogramming factors as shown by semi-quantitative RT-PCR (Fig. 1E). The identity of the UKKi009-A iPS cell line with parental fibroblasts was confirmed by identification of the disease-associated mutation in the KCNH2 gene by DNA sequencing (Fig. 1F), SNP genotyping (Fig. 1G) and short tandem repeat (STR) analysis (Fig. 2). Molecular karyotyping revealed a normal female karyotype (Fig. 3). The cell line was also confirmed to be free of mycoplasma and viral (HIV-1, HCV and HBV) sequences.

Materials and methods

Human dermal fibroblasts (hDFs) were isolated from the skin biopsy of the patient and cultured in human fibroblast culture medium [Dulbecco's modified Eagle medium (DMEM)-GlutaMAX supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids (NEAA), 100 U/ml penicillin, 100 µg/ml streptomycin and 100 µM β-mercaptoethanol (β-ME)]. Reprogramming was achieved by transfecting

hDFs with plasmids expressing SB100× transposase, OKSM-mCherry, and microRNA 307/367 as described in (Grabundzija et al., 2013). Briefly, 3×10^6 hDFs were transfected with 3 µg of SB-OKSM, 1 µg SB100× and 1 µg of microRNA plasmid using Neon Transfection device and a 100 µl Neon Tip according to the manufacturer's instructions (ThermoFischer Scientific). Cells were then cultured in human fibroblast culture medium for the first 7 days. Later, the cells were re-plated on irradiated MEFs and cultured in reprogramming medium (DMEM/F-12 + GlutaMAX supplemented with 20% KnockOut Serum Replacement (KOSR), 8 ng/ml basic fibroblast growth factor (bFGF), 1% NEAA, and 100 µM β-ME) containing vitamin C (50 µg/ml) and valproic acid (1 mM) at 37 °C in normoxic conditions and 5% CO₂. The cells were treated with small molecules for 7 days. Later, the cells were cultured on MEFs in reprogramming media without small molecules until iPS cell colonies appeared which were then picked and cultured. Each picked clone was expanded on MEFs in human iPS cell medium (DMEM/F-12 + GlutaMAX supplemented with 20% KOSR, 1% NEAA, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µM β-ME and 10 ng/ml bFGF) and later adapted to culture on vitronectin in E8 medium. iPS cell culture was repeatedly checked for mycoplasma contamination using MycoAlert before making frozen stocks.

In vitro differentiation

Media was removed and the cells were washed with PBS. TrypLE was added for 3 min. DMEM containing 20% FCS was added to quench the TrypLE. Cells were centrifuged at 300 ×g for 3 min and

Download English Version:

<https://daneshyari.com/en/article/2093971>

Download Persian Version:

<https://daneshyari.com/article/2093971>

[Daneshyari.com](https://daneshyari.com)